Clinical trial

A Phase IIII Study of AL8326 in Small Cell Lung Cancer

NCT06247605

Drugs and interventions used in this trial

2 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Unmapped registry intervention AL8326 tablets Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention placebo Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

A Phase IIII Study of AL8326 in Small Cell Lung Cancer

Design: INTERVENTIONAL · Status: RECRUITING · Phase: PHASE3

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusRECRUITING

Study typeINTERVENTIONAL

Start date2023-10-26

PhasePHASE3

Conditions

Small Cell Lung Carcinomaverified · MONDO: small cell lung carcinoma

Interventions

AL8326 tabletsDRUG

placeboDRUG

Sponsors & collaborators

Advenchen Laboratories Nanjing Ltd.lead sponsor

Mapped research locations

ChangchunJilin, China1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT06247605 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.